Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Trip 

AbbVie Inc. diskutieren

AbbVie Inc.

WKN: A1J84E / Symbol: ABBV / Name: AbbVie / Aktie / Pharmazeutika / Large Cap /

184,80 €
-0,96 %

Einschätzung Buy
Rendite (%) 8,88 %
Kursziel 184,78
Veränderung
Endet am 09.07.25

AbbVie Inc. (NYSE: ABBV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $200.00 price target on the stock.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) 7,77 %
Kursziel 180,36
Veränderung
Endet am 11.07.25

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Morgan Stanley from $191.00 to $196.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,50 %
Kursziel 184,10
Veränderung
Endet am 26.07.25

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Barclays PLC from $187.00 to $200.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,50 %
Kursziel 188,70
Veränderung
Endet am 26.07.25

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Wells Fargo & Company from $200.00 to $205.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,50 %
Kursziel 193,31
Veränderung
Endet am 26.07.25

AbbVie Inc. (NYSE: ABBV) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $210.00 price target on the stock, up previously from $195.00.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,83 %
Kursziel 184,08
Veränderung
Endet am 26.07.25

AbbVie Inc. (NYSE: ABBV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $200.00 price target on the stock.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) 5,88 %
Kursziel 182,54
Veränderung
Endet am 05.08.25

AbbVie Inc. (NYSE: ABBV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $200.00 price target on the stock.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) 1,77 %
Kursziel 199,34
Veränderung
Endet am 12.08.25

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Morgan Stanley from $211.00 to $218.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) 5,34 %
Kursziel 186,74
Veränderung
Endet am 23.08.25

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Piper Sandler from $196.00 to $209.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) 17,50 %
Kursziel 204,91
Veränderung
Endet am 07.10.25

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at TD Cowen from $195.00 to $225.00. They now have a "buy" rating on the stock.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) 17,51 %
Kursziel 193,20
Veränderung
Endet am 07.10.25

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Barclays PLC from $200.00 to $212.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) 16,32 %
Kursziel 196,53
Veränderung
Endet am 10.10.25

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Truist Financial Co. from $210.00 to $215.00. They now have a "buy" rating on the stock.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) 15,90 %
Kursziel 203,28
Veränderung
Endet am 17.10.25

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at BMO Capital Markets from $214.00 to $220.00. They now have an "outperform" rating on the stock.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) 13,01 %
Kursziel 198,98
Veränderung
Endet am 25.10.25

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Citigroup Inc. from $170.00 to $215.00. They now have a "buy" rating on the stock.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,03 %
Kursziel 212,66
Veränderung
Endet am 31.10.25

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Morgan Stanley from $218.00 to $231.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,37 %
Kursziel 207,63
Veränderung
Endet am 31.10.25

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Citigroup Inc. from $215.00 to $226.00. They now have a "buy" rating on the stock.
Ratings data for ABBV provided by MarketBeat

AbbVie Inc. (NYSE: ABBV) was upgraded by analysts at Argus from a "hold" rating to a "buy" rating.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,99 %
Kursziel 205,80
Veränderung
Endet am 06.11.25

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Guggenheim from $212.00 to $221.00. They now have a "buy" rating on the stock.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) 21,13 %
Kursziel 210,81
Veränderung
Endet am 12.11.25

AbbVie Inc. (NYSE: ABBV) had its price target lowered by analysts at Morgan Stanley from $231.00 to $224.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat

Einschätzung Buy
Rendite (%) 22,72 %
Kursziel 196,21
Veränderung
Endet am 12.11.25

AbbVie Inc. (NYSE: ABBV) had its price target lowered by analysts at BMO Capital Markets from $228.00 to $208.00. They now have an "outperform" rating on the stock.
Ratings data for ABBV provided by MarketBeat